Formatting the Risk Prediction Models for Never-Smoking Lung Cancer

ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-80
SponsorChung Shan Medical University

About this trial

Lung Cancer is the leading cause of cancer-related deaths in Taiwan and worldwide and the incidence is also increasing. The payment for lung cancer which occupies the largest part of National Health Insurance expense is over 15 billion in 2018. Because about 80% lung cancer patients are smokers in western countries the low-dose computed tomography screening focuses on the smoking population It is quite different in South-East Asia particularly in Taiwan that 53% of Taiwan lung cancer are never-smokers and the etiology and the underlying mechanisms are still unknown. The preliminary results of prospective TALENT study indicated that family history plays a key role in tumorigenesis of Taiwan lung cancers but several important variables such as air pollution, biomarkers, radiomics analysis are not available limits the accuracy of lung cancer identification. Hence, it is critical to integrate most of factors involved in lung cancer formation into a multidimensional lung cancer prediction model which could benefit never-smoker lung cancers in Taiwan and East Asia even in the western countries. The investigators initiate a clinical study to validate the multidimensional lung cancer prediction model for never-smoking population by multicenter prospective study.

Eligibility criteria

Qualifiers

Age 50-80 years old

First-degree relatives of lung cancer patients

aged more than 50 - 80 years old

or older than the age at diagnosis of the youngest lung cancer the proband in the family if they are less than 50 years old

Disqualifiers

Previous history of lung cancer

Another malignancy except for cervical carcinoma in situ or non-melanomatous carcinoma of the skin within 5 years

An inability to tolerate transthoracic procedures or thoracotomy

Chest CT examination was performed within 18 months

Trial design

Treatments tested in this trial

  • LDCT lung cancer screen, immediately
  • LDCT lung cancer screen, later

Treatment groups

10,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Chung Shan Medical University

Lead sponsor

Ministry of Health and Welfare, Taiwan

Collaborator